RCKT - Rocket Pharmaceuticals Inc

RCKT - Rocket Pharmaceuticals Inc

https://www.rocketpharma.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Zacks Commentary • 3 weeks, 4 days ago • score: 0.20

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Bilibili ( NASDAQ:BILI ) , Coty ( NYSE:COTY )

Benzinga • 3 weeks, 4 days ago • score: 0.14

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday. Shares of Coty Inc. COTY fell sharply in the pre-market trading session as the company posted mixed fourth-quarter fiscal results.

RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action - RCKT - Rocket Pharmaceuticals ( NASDAQ:RCKT )

Benzinga • 1 month ago • score: 0.05

NEW YORK, Aug. 10, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. RCKT between September 17, 2024 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the important August 11, ...

RCKT DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in...

Business Insider • 1 month ago • score: 0.05

New York, New York-- ( Newsfile Corp. - August 9, 2025 ) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. ( NASDAQ: RCKT ) between September 17, 2024 and May 26, 2025, both dates inclusive ( the "Class Period" ) , of the ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey.

52W High

$22.01

52W Low

$2.19

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.62

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-7.77

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.00

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

3.02%

Institutions (25–75% balanced)

90.90%

Shares Outstanding

107,904,000

Float

78,781,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-2.51

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.70%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.0058

Previous

0.0183

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025